# Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

> **NCT00239200** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 29 (estimated)

## Conditions studied

- Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus

## Interventions

- **DRUG:** Lapatinib

## Key facts

- **NCT ID:** NCT00239200
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** 2006-06
- **Final completion:** 2007-09
- **Target enrollment:** 29 (ESTIMATED)
- **Why stopped:** notification from sponsor
- **Last updated:** 2008-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239200, "Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00239200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*